Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SX-682 and Docetaxel in Advanced Head and Neck or Prostate Cancer
NCT07667400Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Nov 2026
- Primary completion
- Oct 2036
- Countries
- 1
01
Overview
A Phase 2 trial of SX-682 in head and neck squamous cell carcinoma (HNSCC), salivary gland carcinoma (SGC), metastatic castration-resistant prostate cancer (mCRPC), sponsored by National Cancer Institute. Started Nov 2026; status: recruiting.
02
Drugs
SX-682
03
Conditions
head and neck squamous cell carcinoma (HNSCC)salivary gland carcinoma (SGC)metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07667400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07667400.